| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1432-2277.2006.00326.X |
| P698 | PubMed publication ID | 16827681 |
| P50 | author | Valentín Cuervas-Mons | Q57037415 |
| P2093 | author name string | Antoni Rimola | |
| Francisco Suárez | |||
| Manuel de la Mata | |||
| Joan Figueras | |||
| Jorge Ortiz de Urbina | |||
| Martin Prieto | |||
| Angel Bernardos | |||
| P2860 | cites work | A humanized antibody that binds to the interleukin 2 receptor | Q24600912 |
| A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone and mycophenolate mofetil in primary adult liver transplantation: a single center report | Q28360654 | ||
| Experience with daclizumab in liver transplantation: renal transplant dosing without calcineurin inhibitors is insufficient to prevent acute rejection in liver transplantation | Q33835660 | ||
| Steroid withdrawal in liver transplantation: benefits, risks, and unanswered questions | Q34008576 | ||
| Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomised controlled trial | Q34155167 | ||
| Long-term management of the liver transplant patient: diabetes, hyperlipidemia, and obesity | Q34426367 | ||
| Steroid elimination 24 hours after liver transplantation using daclizumab, tacrolimus, and mycophenolate mofetil | Q34451191 | ||
| Cardiovascular morbidity and mortality after orthotopic liver transplantation | Q34581979 | ||
| Osteoporosis after liver transplantation | Q35102282 | ||
| Osteoporosis in liver diseases and after liver transplantation | Q35134421 | ||
| Single-dose daclizumab induction therapy in patients with liver transplantation | Q36179019 | ||
| Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial | Q40657873 | ||
| Results of lis2t, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation | Q42985745 | ||
| Double-blind comparison of hepatitis C histological recurrence Rate in HCV+ Liver transplant recipients given basiliximab + steroids or basiliximab + placebo, in addition to cyclosporine and azathioprine. | Q42989456 | ||
| A pilot study on the safety and effectiveness of immunosuppression without prednisone after liver transplantation | Q42993813 | ||
| Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy1 | Q43513598 | ||
| Safety and risk of using pediatric donor livers in adult liver transplantation | Q43517493 | ||
| A novel management strategy of steroid-free immunosuppression after liver transplantation: efficacy and safety of tacrolimus and mycophenolate mofetil | Q43547324 | ||
| Tacrolimus versus cyclosporin microemulsion in liver transplantation: results of a 3-month study | Q43553009 | ||
| Daclizumab induction therapy in combination with tacrolimus | Q43553044 | ||
| Liver transplantation using sirolimus and minimal corticosteroids (3-day taper). | Q43575684 | ||
| A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients | Q43604925 | ||
| Corticosteroid-free immunosuppression with tacrolimus following induction with daclizumab: a large randomized clinical study | Q43943540 | ||
| Staggered immunosuppression with the interleukin-2 receptor antagonist daclizumab combined with tacrolimus, prednisolone, and mycophenolate mofetil after orthotopic liver transplantation: a pilot efficacy and safety study | Q44033379 | ||
| Long-term safety, tolerability and efficacy of daclizumab (Zenapax) in a two-dose regimen in liver transplant recipients | Q44067844 | ||
| A randomised trial comparing the efficacy and safety of tacrolimus with microemulsified cyclosporine after liver transplantation | Q44101295 | ||
| First results from a prospective randomized trial comparing steroid-free induction therapy with tacrolimus and MMF versus tacrolimus and steroids in patients after liver transplantation for HCV. | Q44101383 | ||
| Steroid-free immunosuppression during and after liver transplantation--a 3-yr follow-up report. | Q44461506 | ||
| Early steroid withdrawal after liver transplantation: the Canadian tacrolimus versus microemulsion cyclosporin A trial: 1-year follow-up | Q44463528 | ||
| Impact of hepatitis C viral infection in primary cadaveric liver allograft versus primary living-donor allograft in 100 consecutive liver transplant recipients receiving tacrolimus | Q44846968 | ||
| Two-dose daclizumab induction therapy in 209 liver transplants: a single-center analysis | Q45122577 | ||
| Steroid withdrawal at day 14 after liver transplantation: a double-blind, placebo-controlled study | Q45159362 | ||
| Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected]. | Q53356778 | ||
| Prednisone withdrawal 14 days after liver transplantation with mycophenolate: a prospective trial of cyclosporine and tacrolimus. | Q53961304 | ||
| Corticosteroid withdrawal after liver transplantation | Q71769062 | ||
| Banff schema for grading liver allograft rejection: an international consensus document | Q73107837 | ||
| A pilot study of immunosuppressive monotherapy in liver transplantation: tacrolimus versus microemulsified cyclosporin | Q73156830 | ||
| The safety and efficacy of a two-dose daclizumab (zenapax) induction therapy in liver transplant recipients | Q73832039 | ||
| Steroid withdrawal is safe and beneficial in stable cyclosporine-treated liver transplant patients | Q74429552 | ||
| Liver transplant induction trial of daclizumab to spare calcineurin inhibition | Q74604939 | ||
| Early cyclosporine monotherapy in liver transplantation: a 5-year follow-up of a prospective, randomized trial | Q74629340 | ||
| P433 | issue | 8 | |
| P921 | main subject | immunosuppression | Q1455316 |
| P304 | page(s) | 641-648 | |
| P577 | publication date | 2006-08-01 | |
| P1433 | published in | Transplant International | Q15762140 |
| P1476 | title | Daclizumab induction and maintenance steroid-free immunosuppression with mycophenolate mofetil and tacrolimus to prevent acute rejection of hepatic allografts | |
| P478 | volume | 19 |
| Q36718780 | A prospective, randomized trial of complete avoidance of steroids in liver transplantation with follow-up of over 7 years |
| Q80512153 | Anti-CD25 treatment and FOXP3-positive regulatory T cells in heart transplantation |
| Q37691180 | Antibody immunosuppressive therapy in solid-organ transplant: Part I. |
| Q24194518 | Antibody induction versus corticosteroid induction for liver transplant recipients |
| Q37342927 | High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis |
| Q36738534 | New aspect of immunosuppressive treatment in liver transplantation. How could you induce tolerance in liver transplantation? |
| Q37709229 | Role of steroid minimization in the tacrolimus-based immunosuppressive regimen for liver transplant recipients: a systematic review and meta-analysis of prospective randomized controlled trials |
| Q80526260 | [Progress in immunosuppression] |
Search more.